Springe direkt zu Inhalt

Original Journal Contributions/Originalbeiträge

  • A.M. Mc Laughlin#, T. Helland#, F. Klima, S. Koolen, R. van Schaik, R. Mathijssen, P. Neven, J. Swen, H.-J. Guchelaar, F. Dalenc, M. White-Koning, R. Michelet, G. Mikus, W. Schroth, T. Mürdter, H. Brauch, M. Schwab, G. Mellgren, F. Thomas, C. Kloft*, D. Hertz* on behalf of the CYP2D6 Endoxifen Percentage Activity Model (CEPAM) consortium.
    Nonlinear mixed-effects model of Z-endoxifen concentrations in tamoxifen-treated patients from the CEPAM cohort.
    #shared first authorship
    *shared senior authorship
    Clin. Pharm. Ther. 116: 690-702 (2024).
    doi: 10.1002/cpt.3238

  • D. Bindellini, R. Michelet, L.B.S. Aulin, J. Melin, U. Neuman, O. Blankenstein, W. Huisinga, M.J. Whitaker, R. Ross, C. Kloft.
    A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy.
    J. Pharmacokinet. Pharmacodyn.
    doi: 10.1007/s10928-024-09934-7

  • A.M. Mc Laughlin#, D. Hess#, R. Michelet, I. Colombo, S. Haefliger, S. Bastian, M. Rabaglio, M. Schwitter, S. Fischer, K. Eckhardt, S. Hayoz, C. Kopp, M. Klose, C. Sessa, A. Stathis, S. Halbherr, W. Huisinga, M. Joerger*, C. Kloft*.
    Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin in a phase I trial.|
    #shared first authorship
    *shared senior authorship
    Cancer Chemother. Pharmacol. 94: 349-360 (2024).
    doi: 10.1007/s00280-024-04679-z

  • A. Saleh, J. Schulz, J.F. Schlender, L. B.S. Aulin, A.P. Konrad, F. Kluwe, G. Mikus, W. Huisinga, C. Kloft#, R. Michelet#.
    Understanding voriconazole metabolism: a middle-out physiologically-based pharmacokinetic modelling framework integrating in vitro and clinical insights.
    #shared senior authorship
    Clin. Pharmacokinet. 63:1609-1630 (2024).
    doi: 10.1007/s40262-024-01434-8

  • I.K. Minichmayr, S.G. Wicha, P. Matzneller, C. Kloft, M. Zeitlinger.
    Impact of key components of intensified ceftaroline dosing on pharmacokinetic/pharmacodynamic target attainment.
    Clin. Pharmacokinet. 63: 121–131 (2024).
    doi: 10.1007/s40262-023-01325-4

  • J. Rolff, S. Bonhoeffer, C. Kloft, R. Leistner, R. Regoes, M.E. Hochberg.
    Forecasting antimicrobial resistance evolution.
    Trends Microbiol. 32: 736-745 (2024).
    doi: 10.1016/j.tim.2023.12.009

  • U. Falkenhagen,  L.H. Cavallari,  J.D. Duarte,  C. Kloft,  S. Schmidt,  W. Huisinga.
    Leveraging QSP Models for MIPD: A Case Study for Warfarin/INR.
    Clin. Pharmacol. Ther. 116: 795-806 (2024).
    doi: 10.1002/cpt.3274

  • J. Knöchel, C. Kloft, W. Huisinga.
    Index analysis: an approach to understand signal transduction with application to the EGFR signalling pathway.
    PLoS Comput Biol 20: e1011777. (2024)
    doi: 10.1371/journal.pcbi.1011777

  • I. Colombo, K.-L. Koster, L. Holer, S. Hgebuaefliger, M. Rabaglio, S. Bastian, M. Schwitter, K. Eckhardt, S. Hayoz, A.M. Mc Laughlin, C. Kloft, M. Klose, S. Halbherr, C. Baumgartner, C. Sessa, A. Stathis, D. Hess, M. Joerger.
    TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
    Eur. J. Cancer. 201: 113588 (2024).
    doi: 10.1016/j.ejca.2024.113588

  • A. Lehmann, I. Geburek, S. Hessel-Pras, A.M. Enge, H. Mielke, C. Müller-Graf, C. Kloft, C. Hethey.
    PBTK model-based analysis of CYP3A4 induction and the toxicokinetics of the pyrrolizidine alkaloid retrorsine in man.
    Arch. Toxicol. 98: 1757-1769 (2024).
    doi: 10.1007/s00204-024-03698-2

  • Z. Duvnjak, F.S. Stark, V. Cosson, S. Retout, E. Schindler, J.A. Abrantes.
    Simulation-based evaluation of the Pharmpy Automatic Model Development tool for population pharmacokinetic modeling in early clinical drug development.
    CPT Pharmacometrics Syst. Pharmacol. 13: 1707-1721 (2024).
    doi:10.1002/psp4.13213

  • F. Kluwe, R. Michelet, W. Huisinga, M. Zeitlinger, G. Mikus, C. Kloft.
    Towards model-informed precision dosing of voriconazole: Challenging published voriconazole nonlinear mixed-effects models with real-world clinical data.
    Clin. Pharmacokinet. 62: 1461-1477 (2023).
    doi: 10.1007/s40262-023-01274-y

  • R. Michelet, D. Bindellini, J. Melin, U. Neumann, O. Blankenstein, W. Huisinga, T.N. Johnson, M.J. Whitaker, R. Ross, C. Kloft.
    Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach.
    Front. Pharmacol.13: 1090554 (2023).
    doi: 10.3389/fphar.2022.1090554

  • V. Stachanow, U. Neumann, O. Blankenstein, N. Alder-Baerens, D. Bindellini, P. Hindmarsh, R. Ross, M.J. Whitaker, J. Melin, W. Huisinga, R. Michelet, C. Kloft.
    Model-informed target morning 17α-hydroxyprogesterone concentrations in dried blood spots for pediatric congenital adrenal hyperplasia patients.
    Pharmaceuticals 16: 464 (2023).
    doi: 10.3390/ph16030464

  • F.W. Ojara, A. Henrich, N. Frances, Y.M. Nassar, W. Huisinga, N. Hartung, K. Geiger, S. Holdenrieder, M. Joerger, C. Kloft.
    A prognostic baseline serum biomarker and tumour growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.
    CPT Pharmacometrics Syst Pharmacol. 12: 1714-1725 (2023).
    doi:10.1002/psp4.12937

  • Y.M. Nassar, F.W. Ojara, A. Pérez-Pitarch, K. Geiger, W. Huisinga, N. Hartung, R. Michelet, S. Holdenrieder, M. Joerger*, C. Kloft*.
    C-reactive protein as an early predictor of efficacy in advanced non-small cell lung cancer patients: A tumor dynamics-biomarker modeling framework.
    Cancers 15:5429 (2023).
    *shared senior authorship
    doi: 10.3390/cancers15225429

  • S. Stübler, C. Kloft, W. Huisinga.
    Cell-level systems biology model to study inflammatory bowel diseases and their treatment options.
    CPT: Pharmacometrics Syst. Pharmacol. 12: 690-705 (2023).
    doi: 10.1002/psp4.12932

  • U. Falkenhagen, C. Himpe, J. Knöchel, C. Kloft, W. Huisinga.
    Sample-based robust model reduction for non-linear systems biology models.
    Proc. Appl. Math. Mech. e202200269 (2023).
    doi: 10.1002/pamm.202200269

  • U. Falkenhagen, J. Knöchel, C. Kloft, W. Huisinga.
    Deriving mechanism-based pharmacodynamic models by reducing quantitative systems pharmacology models: An application to warfarin.
    CPT: Pharmacometrics Syst. Pharmacol.12: 432-443 (2023).
    doi:10.1002/psp4.12903

  • A. Lehmann, I. Geburek, A. These, S. Hessel-Pras, J.G. Hengstler, W. Albrecht, H. Mielke, C. Müller-Graf, X. Yang, C. Kloft, C. Hethey.
    PBTK modeling of the pyrrolizidine alkaloid retrorsine to predict liver toxicity in mouse and rat.
    Arch. Toxicol. 7: 1319-1333 (2023).
    doi:10.1007/s00204-023-03453-z

  • S. Gehrke-Beck, M. Petersen, W.J. Herrmann, N. Zimmermann, E. Daub, J. Seeger, J. Schulz, C. Czimmeck, N. Lauterbach, H. Peters, C. Kloft, M. Schulz, I. Siebenbrodt, R. Behrend.
    Development of a project for interprofessional collaboration between medical and pharmacy students to improve medication safety in polypharmacy (PILLE).
    GMS J Med Educ. 40: Doc3 (2023).
    doi: 10.3205/zma001585

  • J. Schulz, R. Michelet, M. Zeitlinger, G. Mikus, C. Kloft. 
    Microdialysis of voriconazole and its N-oxide metabolite: Amalgamating knowledge of distribution and metabolism processes in humans.
    Pharm. Res. 39: 3279–3291 (2022).
    doi: 10.1007/s11095-022-03407-7

  • J. Schulz, R. Michelet, M. Zeitlinger, G. Mikus, C. Kloft. 
    Microdialysis of drug and drug metabolite: A comprehensive in vitro analysis for voriconazole and voriconazole N‐oxide.
    Pharm. Res. 39: 2991-3003 (2022).
    doi: 10.1007/s11095-022-03292-0

  • J. Schulz, A. Thomas, A. Saleh, G. Mikus, C. Kloft*, R. Michelet*.
    Towards the elucidation of the pharmacokinetics of voriconazole: a quantitative characterization of its metabolism.
    Pharmaceutics. 14:477 (2022).
    doi: 10.3390/pharmaceutics14030477
    * shared senior authorship

  • J. Schulz, R. Michelet, J.F. Joseph, M. Zeitlinger, F. Schumacher, C. Kloft.
    A versatile high-performance LC-MS/MS assay for the quantification of voriconazole and its N-oxide metabolite in small sample volumes of multiple human matrices.
    J. Pharm Biomed Anal. 210: 114551 (2022).
    doi: 10.1016/j.jpba.2021.114551

  • F.A. Weinelt, M.S. Stegemann, A. Theloe, F. Pfäfflin, S. Achterberg, F. Weber, L. Dübel, A. Mikolajewska, A. Uhrig, P. Kiessling, W. Huisinga, R. Michelet, S. Hennig, C. Kloft.
    Evaluation of a meropenem and piperacillin monitoring program in intensive care unit patients calls for the regular assessment of empirical targets and easy-to-use dosing decision tools.
    Antibiotics 11: 758 (2022).
    doi: 10.3390/antibiotics11060758

  • D. Busse*, P. Simon*, L. Schmitt, D. Petroff, C. Dorn, A. Dietrich, M. Zeitlinger, W. Huisinga, R. Michelet, H. Wrigge, C. Kloft.
    Comparative plasma and interstitial tissue fluid pharmacokinetics of meropenem demonstrate the need for increasing dose and infusion duration in obese and non-obese patients
    Clin. Pharmacokinet. 61: 655-672 (2022).
    doi: 10.1007/s40262-021-01070-6
    *equal contribution

  • D. Busse*, P. Simon*, D. Petroff, N. El-Najjar, L. Schmitt, D. Bindellini, A. Dietrich, M. Zeitlinger, W. Huisinga, R. Michelet, H. Wrigge, C. Kloft.
    High-dosage fosfomycin results in adequate plasma and target-site exposure in morbidly obese and nonobese nonhyperfiltration patients.
    Antimicrob. Agents Chemother. 66: e0230221 (2022).
    doi: 10.1128/aac.02302-21
    *equal contribution

  • D. Busse, J.M. Borghardt, D. Petroff, A. Pevzner, C. Dorn, N. El-Najjar, W. Huisinga, H. Wrigge, P. Simon, C. Kloft.
    Evaluating prediction methods for glomerular filtration to optimise drug doses in obese and nonobese patients.
    Br. J. Clin. Pharmacol. 88: 2973-2981 (2022).
    doi: 10.1111/bcp.15115

  • V. Stachanow, U. Neumann, O. Blankenstein, D. Bindellini, J. Melin, R. Ross, M.J. Whitaker, W. Huisinga, R. Michelet*ǂ, C. Kloftǂ.
    Exploring dried blood spot cortisol concentrations as an alternative for monitoring pediatric adrenal insufficiency patients: A model-based analysis.
    Frontiers Pharmacol. 13: 1-8 (2022).
    ǂshared senior authorship
    *corresponding author
    doi: 10.3389/fphar.2022.819590

  • Y.M. Nassar#, N. Hohmann#, R. Michelet, K. Gottwalt, A.D. Meid, J. Burhenne, W. Huisinga, W.E Haefeli, G. Mikus*, C. Kloft*.
    Quantification of the time course of CYP3A inhibition, activation, and induction using a population pharmacokinetic model of microdosed midazolam continuous infusion
    Clin. Pharmacokinet. 61: 1595-1607 (2022).
    #shared first authorship
    *shared senior authorship
    doi: 10.1007/s40262-022-01175-6

  • C. Maier, J. de Wiljes, N. Hartung, C. Kloft, W. Huisinga.
    A continued learning approach for model-informed precision dosing: updating models in clinical practice.
    CPT: Pharmacometrics Syst. Pharmacol. 11: 185-198 (2022).
    doi:10.1002/psp4.12745

  • M. Berlak#, E. Tucker#, M. Dorel, A. Winkler, A. McGearey, E. Rodriguez-Fos, B. Martins da Costa, K. Barker, E. Fyle, E. Calton, S. Eising, K. Ober, D. Hughes, E. Koutroumanidou, P. Carter, R. Stankunaite, P. Proszek, N. Jain, C. Rosswog, H. Dorado-Garcia, J.J. Molenaar, M. Hubank, G. Barone, J. Anderson, P. Lang, H.E. Deubzer, A. Künkele, M. Fischer, A. Eggert, C. Kloft, A.G. Henssen, M. Boettcher, F. Hertwig, N. Blüthgen, L. Chesler*, J. H. Schulte*.
    Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.
    Mol. Cancer 21, 126 (2022).
    #shared first authorship
    *shared senior authorship
    doi: 10.1186/s12943-022-01583-z

  • U. Liebchen#, F. Weinelt#, C. Scharf, I. Schroeder, M. Paal, M. Zoller, C. Kloft, J. Jung*, R. Michelet*
    Combination of pharmacokinetic and pathogen susceptibility information to optimize meropenem treatment of gram-negative infections in critically ill patients.
    Antimicrob. Agents Chemother. 66: e0183121 (2022).
    #shared first authorship
    *shared senior authorship
     doi: 10.1128/AAC.01831-21

  • P. Opitz, S. Zimmermann, A.M. Mc Laughlin, L. Müller, S. Fuxius, G. Illerhaus, O. Scherf-Clavel, C. Kloft, G. Hempel.
    Development and validation of a bioanalytical method for the quantification of axitinib from plasma and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MS.
    J. Pharm. Biomed. Anal. 221: 115033 (2022)
    doi: 10.1016/j.jpba.2022.115033

  • M. van Dyk, C. Boylan, R. Michelet, A.M. Mc Laughlin, G. Kichenadasse, N. May,
    V. Ziesenitz, J. van den Anker, S.L. Groenland, A. Huitema, N. Steeghs, G. Mikus, C. Kloft, H. Tapp.
    Plasma concentration guided dosing of drugs used for the treatment of childhood leukaemias: Protocol for a systematic review.
    BMJ Open 12:e053308 (2022).
    doi:10.1136/bmjopen-2021-053308

  • C. Dorn, D. Petroff, A. Kratzer, F. Kees, C. Kloft, M. Zeitlinger, H. Wrigge, P. Simon.
    Tigecycline soft tissue penetration in obese and non-obese surgical patients determined by using in vivo microdialysis.
    Eur. J. Drug Metab. Pharmacokinet. 47: 749-755 (2022). 
    doi: 10.1007/s13318-022-00789-2 

  • K. Allegaert, M.Y. Abbasi, R. Michelet, O. Olafuyi.
    The impact of low cardiac output on propofol pharmacokinetics across age groups: An investigation using physiologically based pharmacokinetic modelling.
    Pharmaceutics 14: 1957 (2022).
    doi: 10.3390/pharmaceutics14091957

  • C. Scharf, F. Weinelt, I. Schroeder, M. Paal, M. Weigand, M. Zoller, M. Irlbeck, C. Kloft, J. Briegel, U. Liebchen.
    Does the cytokine adsorber CytoSorb® reduce vancomycin exposure in critically ill patients with sepsis or septic shock? A prospective observational study.
    Ann. Intensive Care 12: 44 (2022).
    doi: 10.1186/s13613-022-01017-5

  • A.M. Mc Laughlin, E. Schmulenson, O. Teplytska, S. Zimmermann, P. Opitz, S.L. Groenland, A. Huitema, N. Steeghs, L. Mueller, S. Fuxius, G. Illerhaus, M. Joerger, F. Mayer, U. Fuhr, S. Holdenrieder, G. Hempel, O. Scherf-Clavel, G. Mikus, U. Jaehde, C. Kloft for the ON-TARGET Study consortium.
    Developing a nationwide infrastructure for Therapeutic Drug Monitoring of targeted oral anticancer drugs: The ON-TARGET study protocol.
    Cancers 13: 6281 (2021).
    doi: 10.3390/cancers13246281

  • F. Weinelt, M. Stegemann, A. Theloe, F. Pfäfflin, S. Achterberg, L. Schmitt, W. Husinga, R. Michelet, S. Hennig, C. Kloft.
    Development of a model-informed dosing tool to optimise initial antibiotic dosing - a translational example for intensive care units.
    Pharmaceutics 13:2128 (2021).
    doi: 10.3390/pharmaceutics13122128

  • U. Liebchen, C. Scharf, M. Zoller, F. Weinelt*, C. Kloft*.
    No clinically relevant removal of meropenem by cytokine adsorber CytoSorb® in critically ill patients with sepsis or septic shock.
    Intensive Care Med. 47: 1332–1333 (2021).
    *shared senior authorship
     doi: 10.1007/s00134-021-06487-y

  • F. Kluwe, R. Michelet, A. Mueller-Schoell, C. Maier, L. Klopp-Schulze, M. van Dyk, G. Mikus, W. Huisinga, C. Kloft.
    Perspectives on model-informed precision dosing in the digital health era: Challenges, opportunities, and recommendations
    Clin. Pharmacol. Ther. 109: 29-36 (2021).
    doi: 10.1002/cpt.2049

  • A. Mueller-Schoell, R. Michelet, L. Klopp-Schulze, M. van Dyk, T.E. Mürdter, M. Schwab, M. Joerger, W. Huisinga, G. Mikus, C. Kloft.
    Computational treatment simulations to assess the need for personalized tamoxifen dosing in breast cancer patients of different biogeographical groups.
    Cancers 13: 2432 (2021)
    doi: 10.3390/cancers13102432

  • A. Mueller-Schoell, L. Klopp-Schulze, R. Michelet, M. Van Dyk, T.E. Mürdter, M. Schwab, M. Joerger, W. Huisinga, G. Mikus, C. Kloft.
    Simulation-based assessment of the impact of non-adherence on endoxifen target attainment in different tamoxifen dosing strategies.
    Pharmaceuticals 14: 115 (2021).
    doi: 10.3390/PH14020115

  • A. Mueller-Schoell, N. Puebla-Osorio, R. Michelet, M. Green, A. Künkele, W. Huisinga, P. Strati, B. Chasen, S.S. Neelapu*, C. Yee*, C. Kloft*.
    Early survival prediction framework in CD19-specific CAR-T-cell immunotherapy using a population quantitative systems pharmacology model.
    Cancers 13: 2782 (2021).
    doi: 10.3390/cancers13112782
    *shared senior authorship

  • D. Busse, P. Simon, D. Petroff, C. Dorn, L. Schmitt, D. Bindellini, A. Kratzer, A. Dietrich, M. Zeitlinger, W. Huisinga, R. Michelet, H. Wrigge, C. Kloft.
    Similar piperacillin/tazobactam target attainment in obese versus nonobese patients despite differences in interstitial tissue fluid pharmacokinetics.
    Pharmaceutics 13: 1380 (2021).
    doi: 10.3390/pharmaceutics13091380

  • D. Busse#, P. Simon#, R. Michelet, L. Ehmann, F. Mehner, C. Dorn, A. Kratzer, W. Huisinga, H. Wrigge, D. Petroff*, C. Kloft*.
    Quantification of microdialysis related variability in humans: Clinical trial design recommendations
    Eur. J. Pharm. Sci. 157: 105607 (2021).
    doi: 10.1016/j.ejps.2020.10560
    #equal contribution
    *shared senior authorship

  • D. Busse#, A. Schaeftlein#, A. Solms, L. Ilia, R. Michelet, M. Zeitlinger, W. Huisinga, C. Kloft.
    Which analysis approach is adequate to leverage clinical microdialysis data? A quantitative comparison to investigate exposure and response exemplified by levofloxacin.
    Pharm. Res. 38: 381–395 (2021).
    doi: 10.1007/s11095-021-02994-1
    #equal contribution

  • J. Seeger, S. Guenther, K. Schaufler, S.E. Heiden, R. Michelet*, C. Kloft*.
    Novel pharmacokinetic/pharmacodynamic parameters quantify the exposure-effect relationship of levofloxacin against fluoroquinolone resistant Escherichia coli.
    Antibiotics 10: 615 (2021).
    *shared senior authorship
    doi: 10.3390/antibiotics10060615

  • J. Seeger*, R. Michelet*, C. Kloft.
    Quantification of persister formation of Escherichia coli leveraging electronic cell counting and semi-mechanistic pharmacokinetic/pharmacodynamic modelling.
    J. Antimicrob. Chemother. 76: 2088-2096 (2021).
    *equal contribution
    doi: 10.1093/jac/dkab146

  • S. Franck, R. Michelet, F. Casilag, J.C. Sirard, S.G. Wicha*, C. Kloft*.
    A model-based pharmacokinetic/pharmacodynamic analysis of the combination of amoxicillin and monophosphoryl lipid A against S. pneumoniae in mice.
    Pharmaceutics 13: 469 (2021).
    doi: 10.3390/pharmaceutics13040469
    *equal contribution

  • R. Michelet, M. Ursino, S. Boulet, S. Franck, F. Casilag, M. Baldry, J. Rolff, M. van Dyk, S. G. Wicha, J.C. Sirard, E. Comets, S. Zohar*, C. Kloft*.
    The use of translational modelling and simulation to develop immunomodulatory therapy as an adjunct to antibiotic treatment in the context of pneumonia
    Pharmaceutics 13: 601 (2021).
    doi: 10.3390/pharmaceutics13050601
    *shared senior authorship

  • U. Liebchen, M. Klose, M. Paal, M. Vogeser, M. Zoller, I. Schroeder, L. Schmitt, W. Huisinga, R. Michelet, J. Zander, C. Scharf, F. Weinelt*, C. Kloft*
    Evaluation of the MeroRisk Calculator, a user-friendly tool to predict the risk of meropenem target non-attainment in critically ill patients.
    Antibiotics 10: 468 (2021).
    doi: 10.3390/antibiotics10040468
    *shared senior authorship

  • V. Stachanow, U. Neumann, O. Blankenstein, U. Fuhr, W. Huisinga, R. Michelet, N. Reisch*, C. Kloft*
    Rationale of a lower dexamethasone dose in prenatal congenital adrenal hyperplasia therapy based on pharmacokinetic modelling.
    Eur. J. Endocrinol. 185: 365-374 (2021).
    *shared senior authorship
    doi: 10.1530/EJE-21-0395

  • M. Paal, C. Scharf, A. Denninger, L. Ilia, C. Kloft, N. Kneidinger, U. Liebchen, S. Michel, C. Schneider, S. Schröpf, C. Schuster, M. Vogeser, F. Weinelt, J. Zander, M. Zoller, I. Schroeder.
    Target site pharmacokinetics of meropenem: Measurement in human explanted lung tissue by bronchoalveolar lavage, microdialysis, and homogenized lung tissue.
    Antimicrob. Agents Chemother. 65: 12 (2021).
    doi: 10.1128/AAC.01564-21

  • A.M. Grisic#, M. Dorn-Rasmussen#, B. Ungar, J. Brynskov, J.F. Ilvemark, N. Bolstad, D.J. Warren, M.A. Ainsworth, W. Huisinga, S. Ben-Horin, C. Kloft*, C. Steenholdt*.
    Infliximab clearance decreases in second and third trimesters of pregnancy in inflammatory bowel disease.
    United Eur. Gastroenterol. J. 9: 91-101 (2021).
    doi: 10.1177/2050640620964619
    #equal contribution
    *shared senior authorship

  • A.M. Grisic, A. Eser, W. Huisinga, W. Reinisch, C. Kloft.
    Quantitative relationship between infliximab exposure and inhibition of C-reactive protein synthesis to support inflammatory bowel diseases management.
    Br. J. Clin. Pharmacol. 87: 2374-2384 (2021).
    doi: 10.1111/bcp.14648

  • A. Mueller-Schoell, R. Michelet, F. Weinelt, C. Kloft, G. Mikus.
    CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications.
    Arch. Toxicol. 95: 2867-2870 (2021).
     doi: 0.1007/s00204-021-03082-4

  • C. Maier, N. Hartung, C. Kloft, W. Huisinga, J. de Wiljes.
    Reinforcement learning and bayesian data assimilation for model-informed precision dosing in oncology.
    CPT Pharmacometrics Syst. Pharmacol. 10: 241-254 (2021).
    doi: 10.1002/psp4.12588

  • H. Saafan, A. Alahdab, R. Michelet, L. Gohlke, J. Ziemann, S. Holdenrieder, M. Michaelis, J. Cinatl, C. Kloft, C.A. Ritter
    Constitutive cell proliferation regulating inhibitor of protein phosphatase 2A (CIP2A) mediates drug resistance to erlotinib in an EGFR activating mutated NSCLC cell line
    Cells 10: 716 (2021).
    doi: 10.3390/cells10040716

  • M. van Dyk, N. Bulamu, C. Boylan, A. M. Mc Laughlin, G. Kichenadasse, N. May, R. Michelet, C. Kloft, B. Kaambwa.
    Cost-effectiveness of oral anti-cancer drugs and associated individualised dosing approaches in cancer patients: Protocol for a systematic review and meta-analysis.
    BMJ Open 11: e047173 (2021).
    doi: 10.1136/bmjopen-2020-047173

  • F. Casilag, L. Matarazzo, S. Franck, M. Figeac, R. Michelet, C. Kloft, C. Carnoy, J.C. Sirard.
    The biosynthetic monophosphoryl lipid A enhances the therapeutic outcome of antibiotic therapy in pneumococcal pneumonia.
    ACS Infectious Diseases. 7: 2164-2175 (2021).
    doi: 10.1021/acsinfecdis.1c00176

  • C. Dorn, D. Petroff, M. Stoelzel, M.G. Kees, A. Kratzer, A. Dietrich, C. Kloft, M. Zeitlinger, F. Kees, H. Wrigge, P. Simon.
    Perioperative administration of cefazolin and metronidazole in morbidly obese and non-obese patients: A pharmacokinetic study in plasma and interstitial fluid.
    J. Antimicrob Chemother. 76: 2114-2120 (2021).
    doi:10.1093/jac/dkab143

  • C. Kloft, R. Hoerr.
    EGb 761® does not affect blood coagulation and bleeding time in patients with probable Alzheimer's dementia - Secondary analysis of a randomized, double-blind placebo-controlled trial.
    Healthcare 9: 1678 (2021)
    doi: 10.3390/healthcare9121678

  • S. Schroepf, D. Burau, H. Muench, H. Derendorf, M. Zeitlinger, O. Genzel-Boroviczény, D. Adam, C. Kloft.
    Microdialysis sampling to monitor target-site vancomycin concentrations in septic infants: a feasible way to close the knowledge gap.
    Int. J. Antimicrob. Agents 58: 106405 (2021).
    doi: 10.1016/j.ijantimicag.2021.106405

  • L. Dossche, R. Michelet, P. De Bruyne, C. Van Herzeele, E. Gasthuys, S. Rittig, A. Vermeulen, J. Vande Walle.
    Desmopressin oral lyophilisate in young children: New insights in pharmacokinetics and pharmacodynamics
    Arch. Dis. Child. 106: 597–602 (2021).
    doi: 10.1136/archdischild-2019-318225

  • L. Ehmann#, P. Simon#, D. Busse#, D. Petroff, C. Dorn, W. Huisinga, A. Dietrich,
    M. Zeitlinger, H. Wrigge*, C. Kloft*.
    Risk of target non-attainment in obese compared to non-obese patients in calculated linezolid therapy.
    Clin. Microbiol. Infect. 26: 1222-1228 (2020).
    doi: 10.1016/j.cmi.2020.04.009
    #equal contribution
    *shared senior authorship

  • R. Michelet, J. Melin, Z.P. Parra-Guillen, U. Neumann, M.J. Whitaker, V. Stachanow,
    W. Huisinga, J. Porter, O. Blankenstein, R.J. Ross, C. Kloft.
    Paediatric population pharmacokinetic modelling to assess hydrocortisone replacement dosing regimens in young children.
    Eur. J. Endocrinol. 183: 357-368 (2020).
    doi: 10.1530/EJE-20-0231

  • R. Michelet, J. Melin, Z.P. Parra-Guillen, U. Neumann, M.J. Whitaker, V. Stachanow,
    W. Huisinga, J. Porter, O. Blankenstein, R.J. Ross, C. Kloft.
    Response to ‘Hydrocortisone suspension formulations are not necessarily the same in the treatment of children with congenital adrenal hyperplasia’.
    Eur. J. Endocrinol. 183: L29-L30 (2020).
    doi: 10.1530/EJE-20-1047

  • J. Melin, Z.P. Parra-Guillen, R. Michelet, T. Truong, W. Huisinga, N. Hartung, P. Hindmarsh, C. Kloft.
    Pharmacokinetic/pharmacodynamic evaluation of hydrocortisone therapy in pediatric patients with congenital adrenal hyperplasia.
    J. Clin. Endocrinol. Metab. 105: 1-12 (2020).
    doi:10.1210/clinem/dgaa071

  • Mueller-Schoell, L. Klopp-Schulze, W. Schroth, T. Mürdter, R. Michelet, H. Brauch,
    W. Huisinga, M. Joerger, P. Neven, S.L.W. Koolen, R.H.J. Mathijssen, E. Copson,
    D. Eccles, S. Chen, B. Chwobay, A. Tfayli, N.K. Zgheib, M. Schwab, C. Kloft.
    Obesity alters endoxifen plasma levels in young breast cancer patients: A pharmacometric simulation approach.
    Clin. Pharmacol. Ther. 108: 661-670 (2020).
    doi: 10.1002/cpt.1960

  • L. Klopp-Schulze#, A. Mueller-Schoell#, P. Neven, S.L.W. Koolen, R.H.J. Mathijssen,
    M. Joerger, C. Kloft.
    Integrated data analysis of six clinical studies points toward model-informed precision dosing of tamoxifen.
    Front. Pharmacol. 11: 283 (2020).
    doi: 10.3389/fphar.2020.00283
    #equal contribution

  • F.W. Ojara, A. Henrich, N. Frances, W. Huisinga, N. Hartung, M. Joerger, C. Kloft.
    Time-to-event analysis of paclitaxel-associated peripheral neuropathy in advanced
    non-small cell lung cancer highlighting key influential treatment/patient factors.
    J. Pharmacol. Exp. Ther. 375: 430-438 (2020).
    doi: 10.1124/jpet.120.000053

  • A.M. Grisic, A. Khandelwal, M. Bertolino, W. Huisinga, P. Girard, C. Kloft.
    Semimechanistic clearance models of oncology biotherapeutics and impact of study design: Cetuximab as a case study.
    CPT: Pharmacometrics Syst. Pharmacol. 9: 628-638 (2020).
    doi: 10.1002/psp4.12558

  • R. Michelet, L. Dossche, C. Van Herzeele, P. De Bruyne, E. Gasthuys, J. Van Bocxlaer,
    J. Vande Walle, A. Vermeulen.
    An integrated paediatric population PKPD analysis of dDAVP: How do PK differences translate to clinical outcomes?
    Clin. Pharmacokinet. 59: 81–96 (2020).
    doi: 10.1007/s40262-019-00798-6

  • S. Hennig, J. Fischer, C. Kloft.
    What “impact” do NLME publications have outside our community?
    CPT: Pharmacometrics Syst. Pharmacol. 9: 191–194 (2020).
    doi:10.1002/psp4.12501

  • P. Simon#, D. Busse#, D. Petroff, C. Dorn, L. Ehmann, S. Hochstäd, F. Girrbach, A. Dietrich, M. Zeitlinger, F. Kees, C. Kloft*, H. Wrigge*.
    Linezolid concentrations in plasma and subcutaneous tissue are reduced in obese patients, resulting in a higher risk of underdosing in critically ill patients: A controlled clinical pharmacokinetic study.
    J. Clin. Med. 9: 1067 (2020).
    doi: 10.3390/jcm9041067

  • C. Maier, N. Hartung, J. de Wiljes, C. Kloft, W. Huisinga.
    Bayesian data assimilation to support informed decision-making in individualized chemotherapy.
    CPT: Pharmacometrics Syst. Pharmacol. 9: 153-164 (2020). 
    doi.org/10.1002/psp4.12492

  • J. Grensemann, D. Busse, C. König, K. Roedl, W. Jäger, D. Jarczak, S. Iwersen-Bergmann, C. Manthey, S. Kluge, C. Kloft*, V. Fuhrmann*.
    Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study.
    Ann. Intensive Care 10: 1-10 (2020).
    doi: 10.1186/s13613-020-00666-8
    *shared senior authorship

  • P. Simon, D. Petroff, D. Busse, J. Heyne, F. Girrbach, A. Dietrich, A. Kratzer, M. Zeitlinger, C. Kloft, F. Kees, H. Wrigge, C. Dorn.
    Meropenem plasma and interstitial soft tissue concentrations in obese and non-obese patients – a controlled clinical trial.
    Antibiotics 9: 931 (2020).
    doi: 10.3390/antibiotics9120931  

  • L. Ehmann, M. Zoller, I.K. Minichmayr, C. Scharf, W. Huisinga, J. Zander, C. Kloft.    
    Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
    Int. J. Antimicrob. Agents 54: 309-317 (2019).
    doi.org/10.1016/j.ijantimicag.2019.06.016

  • H. Edlund#, A.M. Grisic#, C. Steenholdt, M.A. Ainsworth, J. Brynskov, W. Huisinga, C. Kloft.
    Absence of relationship between CDAI or CRP and infliximab exposure calls for use of objective
    Crohn’s disease activity measures for evaluation of treatment effects at treatment failure.
    Ther. Drug Monit. 41: 235-242 (2019).
    doi: 10.1097/FTD.0000000000000590
    #equal contribution

  • P. Simon, D. Petroff, C. Dorn, L. Ehmann, C. Kloft, C. Prettin, A. Dietrich, M. Zeitlinger,
    F. Kees, H. Wrigge.
    Measurement of soft tissue drug concentrations in morbidly obese and non-obese
    patients – a controlled clinical trial.
    Contemp Clin Trials Commun. 15: 100375 (2019).
    doi.org/10.1016/j.conctc.2019.100375

  • C. Kirbs#, F. Kluwe#, F. Drescher, J. Weiss, P. Matzneller, M. Zeitlinger*, C. Kloft*.
    High voriconazole target-site exposure after approved sequence dosing due to nonlinear
    pharmacokinetics assessed by long-term microdialysis.
    Eur. J. Pharm. Sci. 131: 218-229 (2019).
    doi: 10.1016/j.ejps.2019.02.001
    #equal contribution
    *shared senior authorship

  • D. Burau, D. Petroff, P. Simon, L. Ehmann, C. Weiser, C. Dorn, A. Kratzer, H. Wrigge, C. Kloft.
    Drug combinations and impact of experimental conditions on relative recovery in in vitro
    microdialysis investigations.
    Eur. J. Pharm. Sci. 127: 252-260 (2019).
    doi: 10.1016/j.ejps.2018.10.030

  • S. Franck, T. Fuhrmann-Selter, J.F. Joseph, R. Michelet, F. Casilag, J.C. Sirard, S.G. Wicha,
    C. Kloft.
    A rapid, simple and sensitive liquid chromatography tandem mass spectrometry assay to
    determine amoxicillin concentrations in biological matrix of little volume.
    Talanta 201: 253-258 (2019).
    doi.org/10.1016/j.talanta.2019.03.098

  • J. Melin, N. Hartung, Z.P. Parra-Guillen, M.J. Whitaker, R.J. Ross, C. Kloft.
    The circadian rhythm of corticosteroid-binding globulin has little impact on cortisol exposure
    after hydrocortisone dosing.  
    Clin. Endocrinol. 91: 33-40 (2019).
    doi: 10.1111/cen.13969

  • S.G. Wicha, R.G. Mundkowski, A. Klock, U.T. Hopt, B. Drewelow, C. Kloft, U.F. Wellner,
    T. Keck, U.A. Wittel.
    Is moxifloxacin a treatment option for pancreatic infections? A pharmacometric analysis of serum and pancreatic juice.
    J. Clin. Pharmacol. 59: 1405-1414 (2019).
    doi: 10.1002/jcph.1445

  • C. Dorn, D. Petroff, N. Neumann, A. Kratzer, N. El-Najjar, A. Dietrich, C. Kloft,
    M. Zeitlinger, M. Kees, F. Kees, H. Wrigge, P. Simon.
    Plasma and tissue pharmacokinetics of fosfomycin in morbidly obese and non-obese surgical patients: a controlled clinical trial.
    J. Antimicrob. Chemother. 74: 2335-2340 (2019).
    doi: 10.1093/jac/dkz203

  • M. Schulz#, L. Klopp-Schulze#, S. Keilhack, S. Meyer, L. Botermann, C. Kloft.
    Adherence to tamoxifen in breast cancer patients – What role does the pharmacist play in German
    primary care?
    Can. Pharm. J. 152: 28-34 (2018).
    doi: 10.1177/1715163518815720
    #equal contribution

  • L. Klopp-Schulze, C. Kloft.
    CYP2D6-Genotypisierung vor Tamoxifen-Therapiestart.
    Best Pract Oncol. 13: 325-329 (2018).
    doi.org/10.1007/s11654-018-0102-x  

  • J. Melin, Z.P. Parra-Guillen, N. Hartung, W. Huisinga, R.J. Ross, M.J. Whitaker, C. Kloft.
    Predicting cortisol exposure from paediatric hydrocortisone formulation using a
    semi-mechanistic pharmacokinetic model established in healthy adults.
    Clin. Pharmacokinet. 57: 515-527 (2018).
    doi: 10.1007/s40262-017-0575-8

  • L. Klopp-Schulze, M. Joerger, S.G. Wicha, R. ter Heine, C. Csajka, Z.P. Parra-Guillen, C. Kloft.
    Exploiting pharmacokinetic models of tamoxifen and endoxifen to identify factors
    causing subtherapeutic concentrations in breast cancer patients.
    Clin. Pharmacokinet. 57: 229-242 (2018).
    doi: 10.1007/s40262-017-0555-z

  • I.K. Minichmayr, J.A. Roberts, O.R. Frey, A.C. Roehr, C. Kloft, A. Brinkmann.
    Development of a dosing nomogram for continuous infusion meropenem in critically ill
    patients based on a validated population pharmacokinetic model.
    J. Antimicrob. Chemother. 73: 1330-1339 (2018).
    doi: 10.1093/jac/dkx526

  • J. Knöchel, C. Kloft, W. Huisinga.
    Understanding and reducing complex systems pharmacology models based on a novel
    input-response index.
    J. Pharmacokinet. Pharmacodyn. 45: 139-157 (2018).
    doi.org/10.1007/s10928-017-9561-x

  • M.G. Vossen, L. Ehmann, S. Pferschy, A. Maier-Salamon, M. Haidinger, C. Weiser,
    J.M. Wenisch, K. Saria, C. Kajahn, S. Jilch, R. Lemmerer, M. Bécède, M. Zeitlinger,
    C. Kloft, W. Jäger, F. Thalhammer.
    Elimination of doripenem during dialysis and pharmacokinetic evaluation of posthemodialysis dosing for patients undergoing intermittent renal replacement therapy.
    Antimicrob. Agents Chemother. 62: e02430-17 (2018).
    doi: 10.1128/AAC.02430-17

  • S.R. Quist, C. Kirbs, C. Kloft, H.P. Gollnick.
    Cytokine and chemokine recovery is increased by colloid perfusates during dermal microdialysis.
    Materials 11: 682 (2018).
    doi: 10.3390/ma11050682

  • I.K. Minichmayr, A. Schaeftlein, J.L. Kuti, M. Zeitlinger, C. Kloft.
    Clinical determinants of target non-attainment of linezolid in plasma and interstitial space
    fluid: A pooled population pharmacokinetic analysis with focus on critically ill patients.
    Clin. Pharmacokinet. 56: 617-633 (2017).
    doi: 10.1007/s40262-016-0463-7

  • L. Ehmann, M. Zoller, I.K. Minichmayr, C. Scharf, B. Maier, M.V. Schmitt, N. Hartung,
    W. Huisinga, M. Vogeser, L. Frey, J. Zander, C. Kloft.
    Role of renal function in risk assessment of target non-attainment after standard dosing
    of meropenem in critically ill patients: A prospective observational study.
    Crit Care 21: 263 (2017).
    doi: 10.1186/s13054-017-1829-4

    Discussed in an Editorial by M.H. Abdul-Aziz, J. Lipman, J.A. Roberts.
    Identifying “at-risk” patients for sub-optimal beta-lactam exposure in critically ill patients
    with severe infections.
    Crit Care 21: 283 (2017).
    doi: 10.1186/s13054-017-1871-2

  • S.G. Wicha, W. Huisinga, C. Kloft.
    Translational pharmacometric evaluation of typical antibiotic broad-spectrum combination
    therapies against staphylococcus aureus exploiting in vitro information.
    CPT: Pharmacometrics Syst. Pharmacol. 6: 512-522 (2017).
    doi: 10.1002/psp4.12197

  • A. Henrich, M. Joerger, S. Kraff, U. Jaehde, W. Huisinga, C. Kloft, Z.P. Parra-Guillen.
    Semimechanistic bone marrow exhaustion pharmacokinetic/pharmacodynamic model for
    chemotherapy-induced cumulative neutropenia.
    J. Pharmacol. Exp. Ther. 362: 347-358 (2017).
    doi: 10.1124/jpet.117.240309

  • H. Edlund, C. Steenholdt, M.A. Ainsworth, E. Goebgen, J. Brynskov, O.Ø. Thomsen,
    W. Huisinga, C. Kloft.
    Magnitude of increased infliximab clearance imposed by anti-infliximab antibodies in
    Crohn’s disease is determined by their concentration.
    AAPS J. 19: 223-233 (2017).
    doi:10.1208/s12248-016-9989-8

  • S. Fuhrman, C. Kloft, W. Huisinga.
    Impact of altered endogenous IgG on unspecific mAb cleareance.
    J. Pharmacokinet. Pharmacodyn. 44: 351-374 (2017).
    doi: 10.1007/s10928-017-9524-2

  • R. Schwameis, S. Syré, D. Marhofer, A. Appelt, D. Burau, K. Sarahrudi, C. Kloft,
    M. Zeitlinger.
    Pharmacokinetics of cefuroxime in synovial fluid.
    Antimicrob. Agents Chemother. 61: e00992-17 (2017).
    doi: 10.1128/AAC.00992-17

  • R. Schwameis, S. Syré, K. Sarahrudi, A. Appelt, D. Marhofer, D. Burau, C. Kloft,
    M. Zeitlinger.
    Penetration of linezolid into synovial and muscle tissue after elective arthroscopy.
    J. Antimicrob. Chemother. 72: 2817-2822 (2017).
    doi: 10.1093/jac/dkx219

  • Z. Oesterreicher, I.K. Minichmayr, R. Sauermann, D. Marhofer, E. Lackner, W. Jäger,
    A. Maier-Salamon, R. Schwameis, C. Kloft, M. Zeitlinger.
    Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): Comparison of
    two dosage regimens.
    Eur. J. Clin. Pharmacol. 73: 1609-1613 (2017).
    doi: 10.1007/s00228-017-2327-y

  • Z.P. Parra-Guillen, P.B. Berger, M. Haschke, M. Donzelli, D. Winogradova, B. Pfister,
    M. Früh, S. Gillessen, S. Krahenbühl, C. Kloft, M. Joerger.
    Role of cyctochrome P450 3A4 and 1A2 phenotyping in patients with advanced
    non-small-cell lung cancer receiving erlotinib treatment.
    Basic Clin. Pharmacol. Toxicol. 121: 309-315 (2017).
    doi: 10.1111/bcpt.12801

  • M.K Smith, S.L. Moodie, R. Bizzotto, E. Blaudez, E. Borella, L. Carrara, P. Chan,  
    M. Chenel, E. Comets, R. Gieschke, K. Harling, L. Harnisch, N. Hartung, A.C. Hooker,
    M.O. Karlsson, R. Kaye, C. Kloft, N. Kokash, M. Lavielle, G. Lestini, P. Magni, A. Mari,
    F. Mentre, C. Muselle, R. Nordgren, H.B. Nyberg, Z.P. Parra-Guillen, L. Pasotti,
    N. Rode-Kristensen, M.L. Sardu, G.R. Smith, M.J. Swat, N. Terranova, G. Yngman,
    F. Yvon, N. Holford.
    Model description language (MDL): A standard for modeling and simulation.
    CPT: Pharmacometrics Syst. Pharmacol. 6: 647-650 (2017).
    doi: 10.1002/psp4.12222

  • U. Neumann, D. Burau, S. Spielmann, M.J. Whitaker, R.J. Ross, C. Kloft, O. Blankenstein.
    Quality of compounded hydrocortisone capsules used in the treatment of children.
    Eur. J. Endocrinol. 177: 239-242 (2017).
    doi: 10.1530/EJE-17-0248

  • J. Melin, S. Prothon, C. Kloft, A. Cleton, C. Johansson, C. Jorup, B. Olsson, U.W. Hamrén.
    Pharmacokinetics of the inhaled selective glucocorticoid receptor modulator AZD5423
    following inhalation using different devices.
    AAPS J. 19: 865-874 (2017).
    doi:10.1208/s12248-016-0042-8

  • C. Kloft, M.N. Trame, C.A. Ritter.
    Systems pharmacology in drug development and therapeutic use - A forthcoming paradigm shift.
    Eur. J. Pharm. Sci. 94: 1-3 (2016).
    doi: 10.1016/j.ejps.2016.07.014

  • H. Saafan, S. Foerster, Z.P. Parra-Guillen, E. Hammer, M. Michaelis, J. Jr. Cinatl, U. Völker, H. Fröhlich, C. Kloft, C.A. Ritter.
    Utilising the EGFR interactome to identify mechanisms of drug resistance in non-small cell lung cancer - Proof of concept towards a systems pharmacology approach.
    Eur. J. Pharmaceut. Sci. 94: 20-32 (2016).
    doi: 10.1016/j.ejps.2016.04.025

  • M. Joerger, J. von Pawel, S. Kraff, J.R. Fischer, W. Eberhardt, T.C. Gauler, L. Mueller, N. Reinmuth, M. Reck, M. Kimmich, F. Mayer, H.G. Kopp, D.M. Behringer, Y.D. Ko, R.A. Hilger, M. Roessler, C. Kloft, A. Henrich, B. Moritz, M.C. Miller, S.J. Salamone, U. Jaehde.
    Open-label, randomised study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small cell lung cancer (NSCLC).
    Ann. Oncol. 27: 1895-1902 (2016).
    doi: 10.1093/annonc/mdw290

  • J.M. Borghardt, B. Weber, A. Staab, C. Kunz, S. Formella, C. Kloft.
    Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach.
    Br. J. Clin. Pharmacol. 81: 538–552 (2016).
    doi: 10.1111/bcp.12780

  • J.M. Borghardt, B. Weber, A. Staab, C. Kunz, C. Kloft.
    Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation.
    Br. J. Clin. Pharmacol. 82: 739-753 (2016).
    doi: 10.1111/bcp.12999

  • S.G. Wicha, C. Kloft.
    Simultaneous determination and stability studies of linezolid, meropenem and vancomycin in bacterial growth medium by high-performance liquid chromatography.
    J. Chrom. B 1028: 242-248 (2016).
    doi: 10.1016/j.jchromb.2016.06.033

  • M.G. Kees, I.K. Minichmayr, S. Moritz, S. Beck, S.G. Wicha, F. Kees, C. Kloft, T. Steinke.
    Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.
    J. Clin. Pharmacol. 56: 307-315 (2016).
    doi: 10.1002/jcph.600

  • L. Botermann, K. Monzel, K. Krueger, C. Eickhoff, C. Kloft, M. Schulz.
    Evaluating patients' comprehensibility of a standardized medication plan.
    Eur. J. Clin. Pharmacol. 72: 1229-1237 (2016).
    doi: 10.1007/s00228-016-2082-5

  • L. Botermann, K. Krueger, C. Eickhoff, C. Kloft, M. Schulz.
    Patients‘ handling of a standardized medication plan: A pilot study and method development.
    Patient. Prefer. Adherence 10: 621–30 (2016).
    doi: 10.2147/PPA.S96431

  • K. Locher, J.M. Borghardt, K.J. Frank, C. Kloft, K.G. Wagner.
    Evolution of a mini-scale biphasic dissolution model: Impact of model parameters on partitioning of dissolved API and modelling of in vivo-relevant kinetics.
    Eur. J. Pharm. Biopharm. 105: 166-175 (2016).
    doi: 10.1016/j.ejpb.2016.06.008

  • C. Töpper, C.L. Steinbach, C. Dorn, A. Kratzer, S.G. Wicha, M. Schleibinger, U. Liebchen, F. Kees, B. Salzberger, M.G Kees.
    Variable linezolid exposure in ICU patients – possible role of drug-drug interactions.
    Ther. Drug Monit. 38: 573-578 (2016).
    doi: 10.1097/FTD.0000000000000324

  • C. Scheerans, S.G. Wicha, J. Michael, H. Derendorf, C. Kloft.
    Concentration–response studies and modelling of the pharmacodynamics of linezolid: Staphylococcus aureus versus Enterococcus faecium.
    Int. J. Antimicrob. Agents. 45: 54-60 (2015).
    doi: 10.1016/j.ijantimicag.2014.07.028

  • S.G. Wicha, M.G. Kees, J. Kuss, C. Kloft.
    Pharmacodynamic and response surface analysis of linezolid or vancomycin combined with meropenem against Staphylococcus aureus.
    Pharm. Res. 32: 2410-2418 (2015).
    doi: 10.1007/s11095-015-1632-3

  • S.G. Wicha, M.G. Kees, A. Solms, I.K. Minichmayr, A. Kratzer, C. Kloft.
    TDMx – a novel web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routine.
    Int. J. Antimicrob. Agents. 45: 442-444 (2015).
    doi: 10.1016/j.ijantimicag.2014.12.010

  • S.G. Wicha, K. Zink, T. Haak, F. Kees, C. Kloft, M.G. Kees.
    Pharmacokinetic/pharmacodynamic analysis of moxifloxacin in patients with diabetic foot infections.
    J. Clin. Pharmacol. 55: 639-646 (2015).
    doi: 10.1002/jcph.464

  • M.J. Swat , S. Moodie, S.M. Wimalaratne, N.R. Kristensen, M. Lavielle, A. Mari, P. Magni, R. Bizzotto, M. Smith, E. Comets, C. Sarr, N. Terranova, E. Blaudez, P. Chan, J. Chard, M. Chenel, D. Edwards, C. Franklin, T. Giorgino, M. Glont, P. Girard, P. Grenon, K. Harling, A.C. Hooker, R. Kaye, R. Keizer, C. Kloft, N. Kokash, C. Laibe, C. Laveille, F. Mentre, E. Mezzalana, A. Munafo, R. Nordgren, H.B. Nyberg, Z.P. Parra-Guillen, L. Pasotti, E. Plan, B. Ribba, G. Smith, I.F. Trocóniz, F. Yvon, L. Harnisch, M. Karlsson, H. Hermjakob, N. Le Novère.
    Pharmacometrics markup language (PharmML): Opening new perspectives for model exchange in drug development.
    Clin. Pharmacol. Ther.: Pharmacomet. Syst. Pharmacol. 4: 316-319 (2015).
    doi: 10.1002/psp4.57

  • Z.P. Parra-Guillen, J.M. Cendrós, C. Peraire, R. Obach, J. Prunynosa, E. Chetaille, I.F. Trocóniz.
    Population pharmacokinetic modelling of irosustat in postmenopausal women with oestrogen-receptor positive breast cancer incorporating non-linear red blood cell uptake.
    Pharm. Res. 32: 1493-1504 (2015).
    doi: 10.1007/s11095-014-1555-4

  • C. Kirbs, C. Kloft.
    In vitro microdialysis recovery and delivery investigation of cytokines as prerequisite for potential biomarker profiling.
    Eur. J. Pharm. Sci. 57: 48-59 (2014).

  • A. Schaeftlein, I.K. Minichmayr, C. Kloft.
    Population pharmacokinetics meets microdialysis: Benefits, pitfalls and necessities of new analysis approaches for human microdialysis data.
    Eur. J. Pharm. Sci. 57: 68-73 (2014).

  • M.G. Kees, S.G. Wicha, A. Seefeld, F. Kees, C. Kloft.
    Unbound fraction of vancomycin in intensive care unit patients.
    J. Clin. Pharmacol. 54: 318-323 (2014).

  • U. Liebchen, A. Kratzer, S.G. Wicha, F. Kees, C. Kloft, M.G. Kees.
    Unbound fraction of ertapenem in intensive care unit patients.
    J. Antimicrob. Chemother. 69: 3108-3111 (2014).

  • R.B. Eslam, A. Burian, G. Vila, R. Sauermann, A. Hammer, D. Frenzel, I.K. Minichmayr, C. Kloft, P. Matzneller, Z. Oesterreicher, M. Zeitlinger.
    Target site pharmacokinetics of linezolid after single and multiple doses in diabetic patients with soft tissue infection.
    J. Clin. Pharmacol. 54: 1058-62 (2014).

  • S.S. Allemann, J.W. Foppe van Mil, L. Botermann, K. Berger, N. Griese, K.E. Hersberger
    Pharmaceutical care: the PCNE definition 2013.
    Int. J. Clin. Pharm. 36: 544-555 (2014).

  • F. Simmel, C. Kirbs, Z. Erdogan, E. Lackner, M. Zeitlinger, C. Kloft.
    Pilot investigation on long-term subcutaneous microdialysis: Proof-of-Principle in humans.
    AAPS J. 15: 95-103 (2013).

  • G. Vlasakakis, E. Comets, A. Keunecke, I. Gueorguieva, P. Magni, N. Terranova, O. Della Pasqua, E.C. de Lange, C. Kloft.
    White paper: Landscape on technical and conceptual requirements and competence framework in Drug/Disease Modeling & Simulation.
    Clin. Pharmacol. Ther.: Pharmacomet. Syst. Pharmacol. 2: e40 (2013).

  • M. Frank, A. Kunz, G. Harms, C. Kloft.
    Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns.
    J. Clin. Pharmacol. 53: 294-304 (2013).

  • M.G. Kees, A. Schaeftlein, H.A. Haeberle, F. Kees, C. Kloft, A. Heininger.
    Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.
    J. Antimicrob. Chemother. 68: 1331-1337 (2013).

  • R. Stößer, W. Herrmann.
    Physical and chemical response of FeCl3/FeCl4− spin probes on the functionalizing of ionic liquids.
    J. Phys. Chem. A 117: 3960-3971 (2013).

  • R. Stößer, W. Herrmann.
    Isotope effects in ESR spectroscopy.
    Molecules. 18: 6679-6722 (2013).

  • M.G. Kees.
    Strategien zur Vermeidung von Antibiotikaresistenzen.
    Med. Klin. Intensivmed. Notfmed. 108: 125-130 (2013).

  • A. Sleinitz, C. Heyde, C. Kloft.
    Medication safety in hospitals.
    Med. Monatsschr. Pharm. 35: 140-151 (2012).

  • R. Stösser, W. Herrmann, A. Pahlke.
    Spin exchange of nitroxyl radicals in H2O and D2O.
    J. Phys. Chem. A 116: 952-961 (2012).

  • C. Justinger, M.K. Schilling, M.G. Kees, A. Kauffels, K. Hirschmann, B. Kopp, F. Kees, O. Kollmar.
    Penetration of moxifloxacin into liver tissue.
    Int. J. Antimicrob. Agents 39: 505-509 (2012).

  • R.A. Keel, A. Schaeftlein, C. Kloft, J. Pope, R. Knauft, D. Nicolau, J.L. Kuti.
    Pharmacokinetics of Intravenous and Oral Linezolid in Adults with Cystic Fibrosis.
    Antimicrob. Agents Chemother., 55: 3393-3398 (2011).

  • A. Schaeftlein, C. Kloft.
    Die Beers-Liste im klinischen Alltag. Erhöhung der Arzneimitteltherapiesicherheit geriatrischer Patienten.
    Arzneimitteltherapiekritik, 3: 219-232 (2011).

  • A. Schaeftlein, C. Kloft.
    Die Beers-Liste im klinischen Alltag. Erhöhung der Arzneimitteltherapiesicherheit geriatrischer Patienten.
    Internistische Praxis, 51/3: 617-630 (2011).

  • M. Frank, M. von Kleist, A. Kunz, G. Harms, C. Schütte, C. Kloft.
    Quantifying the Impact of Nevirapine-Based Prophylaxis Strategies To Prevent Mother-to-Child Transmission of HIV-1: a Combined Pharmacokinetic, Pharmacodynamic, and Viral Dynamic Analysis To Predict Clinical Outcomes.
    Antimicrob. Agents Chemother., 55: 5529-5540 (2011).

  • A.J. Kellermann, C. Kloft.
    Is There a Risk of Bleeding Associated with Standardized Ginkgo biloba Extract Therapy? A Systematic Review and Meta-analysis.
    Pharmacother., 31: 490-502 (2011).

  • U. Hochkirch, W. Herrmann, R. Stößer, M. Linscheid, H.-H. Borchert.
    Distribution profiles of nitroxide spin probes in human skin - a combined study using spatially resolved electron spin resonance spectroscopy and mass spectrometry.
    Anal. Bioanal. Chem., 401: 901-907 (2011).

  • R. Stösser, W. Herrmann, U. Marx, A. Brückner.
    Spin Exchange in Solutions of TEMPOL in n-Octanol and 1-Methyl-3-octylimidazolium Hexafluorophosphate in the Temperature Range from 300 to 500 K.
    J. Phys. Chem., A 115: 2939-2952 (2011).

  • R. Stösser, W. Herrmann, M.
    Feist Austauschwechselwirkung - Von der magnetischen Ordnung in Festlörpern zum Spinaustausch in Lösungen und Biosystemen.
    Humboldt-Spektrum, 18: 104-108 (2011).

  • T. Lehr, A. Staab, D. Trommeshauser, H.G. Schaefer, C. Kloft.
    Efficacy modeling of early clinical data to predict clinical outcome: Tesofensine in Alzheimer's Disease Patients.
    AAPS J., 12: 117-129 (2010).

  • T. Lehr, A. Staab, D. Trommeshauser, H.G. Schaefer, C. Kloft.
    Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole.
    Clin. Pharmacokinet., 49: 53-66 (2010).

  • O. Schwalbe, C. Scheerans, I. Freiberg, A. Schmidt-Pokrzywniak, A. Stang, C. Kloft.
    Compliance of alzheimer patients and forgiveness of donepezil.
    BMC Health Serv. Res., 10: 232-240 (2010).

  • F. Simmel, C. Kloft.
    Microdialysis feasibility investigations with the non-hydrophilic antifungal voriconazole for successful applications in nonclinical and clinical settings.
    Int. J. Clin. Pharmacol. Ther., 48: 695-704 (2010).

  • L. Schönberg, T. Grobosch, D. Lampe, C. Kloft.
    The identification of alkaloids in urine Two intoxication cases using TOX.I.S.
    GIT Laboratory J, 14: 31-33 (2010).

  • A. Lindauer, C. Eickhoff, C. Kloft, U. Jaehde.
    Population pharmacokinetics of high-dose carboplatin in adults and children.
    Ther. Drug Monit., 32: 159-168 (2010).

  • T. Lehr, R. Narbe, O. Jöns, C. Kloft, A. Staab.
    Population pharmacokinetic modelling and simulation of single and multiple dose administration of meloxicam in cats.
    J. Vet. Pharmacol. Therap., 33: 277-286 (2010).

  • A. Kunz, M. Frank, K. Mugenyi, R. Kabasinguzi, A. Weidenhammer, M. Kurowski, C. Kloft, G. Harms.
    Persistance of nevirapine in breast milk and plasma of mothers and their children after single-dose administration.
    J. Antimicrob. Chemother., 63: 170-177 (2009).

  • T. Lehr, A. Staab, C. Tillmann, D. Trommeshauser, H.G. Schaefer, C. Kloft.
    A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.
    Clin. Pharmacokinet., 48:529-542 (2009).

  • K. Kuester, A. Kovar, C. Lüpfert, B. Brockhaus, C. Kloft.
    Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.
    Clin. Pharmacokinet., 48: 477-487 (2009).

  • B. Krippendorff, K. Kuester, C. Kloft, W. Huisinga.
    Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis.
    J. Pharmacokinet. Pharmacodyn., 36: 239-260 (2009).

  • C. Scheerans, H. Derendorf, C. Kloft.
    Proposal for a standardised identification of the mono-exponential terminal phase for orally administered drugs.
    Biopharm. Drug Dispos., 29: 145-157 (2008).

  • U. Hinkel, C. Schuijt, J.F. Erckenbrecht.
    OTC laxative use of sodium picosulfate - Results of a pharmacy-based patient survey (cohort study).
    Int. J. Clin. Pharmacol. Ther., 46: 89-95 (2008).

  • L.B. Stolle, N. Plock, C. Joukhadar, M. Arpi, K.J. Emmertsen, C. Buerger, P. Riegels Nielsen, C. Kloft.
    Pharmacokinetics of linezolid in bone tissue investigated by in vivo microdialysis.
    Scand. J. Clin. Infect., 40: 24-29 (2008).

  • G. Fliss, A. Staab, C. Tillmann, D. Trommeshauser, H.G. Schaefer, C. Kloft.
    Population pharmacokinetic data analysis of cilobradine, an If channel blocker.
    Pharm. Res., 25: 359-368 (2008).

  • C. Thallinger, C. Buerger, N. Plock, S. Kljucar, S. Wuenscher, R. Sauermann, C. Kloft, C. Joukhadar.
    Effect of severity of sepsis on tissue concentrations of linezolid.
    J. Antimicrob. Chemother., 61: 173-176 (2008).

  • T. Lehr, A. Staab, C. Tillmann, E.O. Nielsen, D. Trommeshauser, H.G. Schaefer, C. Kloft.
    Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach.
    Brit. J. Pharmacol., 153: 164-167 (2008).

  • K. Kuester, A. Kovar, C. Lüpfert, B. Brockhaus, C. Kloft.
    Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development.
    Brit. J. Cancer, 98: 900-906 (2008).

  • F. Simmel, J. Soukup, A. Zoerner, J. Radke, C. Kloft.
    Development and validation of an efficient HPLC method for quantification of voriconazole in plasma and microdialysate reflecting an important target site.
    Anal. Bioanal. Chem., 392: 479-488 (2008).

  • T. Dreischulte, O. Schwalbe, S. Simons.
    Die richtige Medizin.
    Dtsch. Apoth. Ztg., 148: 4908-4913 (2008).

  • A. Dietrich, T. Mueller, R. Paschke, B. Kalinowski,T. Behlendorf, F. Reipsch, A. Fruehauf, H.-J. Schmoll, C. Kloft, W. Voigt.
    2-(4-(tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II): a novel platinum compound that overcomes cisplatin resistance and induces apoptosis by mechanisms different from that of cisplatin.
    J. Med. Chem., 51: 5413-5422 (2008).

  • T. Lehr, A. Staab, C. Tillmann, D. Trommeshauser, A. Raschig, H.G. Schaefer, C. Kloft.
    Population pharmacokinetic modelling of NS2330 and its major metabolite in Alzheimer's disease patients.
    Brit. J. Clin. Pharmacol., 64: 36-48 (2007).

  • A. Sauter, C. Kloft, S. Gronau, F. Bogesch¬dorfer, T. Erhardt, W. Golze, C. Schroen, A. Staab, H. Riechelmann, K. Hoermann.
    Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck.
    Int. J. Oncol., 30: 927-935 (2007).

  • L. Schönberg, T. Grobosch, D. Lampe, C. Kloft.
    Analysis of basic compounds in urine by on-line extraction-HPLC-DAD.
    Toxichem + Krimtech, 74: 64-68 (2007).

  • N. Plock, C. Buerger, C. Joukhadar, S. Kljucar, C. Kloft.
    Does linezolid inhibit its own metabolism? - Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients.
    Drug Metab. Dispos., 35: 1816-1823 (2007).

  • D.M. Saunte, F. Simmel, N. Frimodt-Moller, L.B. Stolle, E.L. Svejgaard, M. Haedersdal, C. Kloft, M.C. Arendrup.
    In-vivo efficacy and pharmacokinetics of voriconazole in an animal model of dermatophytosis.
    Antimicrob. Agents Chemother., 51: 3317-3321 (2007).

  • L. Schönberg, T. Grobosch, D. Lampe, C. Kloft.
    Toxicological screening in urine: comparison of two automated HPLC screening systems, toxicological identification system (TOX.I.S.*) versus RemediTM-HS.
    J. Anal. Tox., 31: 321-327 (2007).

  • O. Schwalbe, I. Freiberg, C. Kloft.
    [The beers criteria - an instrument to optimise the pharmacotherapy of geriatric patients].
    Med. Monatsschr. Pharm., 30: 244-248 (2007).

  • C. Kloft, A. Henningsson, J. Wallin, E. Chatelut, M.O. Karlsson.
    Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
    Clin. Cancer Res., 12: 5481-5490 (2006).

  • O. Schwalbe, C. Buerger, N. Plock, C. Joukhadar, C. Kloft.
    Urea as an endogenous surrogate in human microdialysis to determine relative recovery of drugs: analytics and applications.
    J. Pharm. Biomed. Anal., 41: 233-239 (2006).

  • H. Stocker, C. Kloft, N. Plock, A. Breske, G. Kruse, C. Herzmann, H. Schulbin, P. Kreckel, C. Weber, F. Goebel, J. Roeling, S. Staszewski, A. Plettenberg, C. Moecklinghoff, K. Arasteh, M. Kurowski.
    Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.
    Antimicrob. Agents Chemother., 50: 667-673 (2006).

  • F. Islinger, P. Dehghanyar, R. Sauermann, C. Buerger, C. Kloft, M. Mueller, C. Joukhadar.
    The effect of food on plasma and tissue concentrations of linezolid after multiple doses.
    Int. J. Antimicrob. Agents, 27: 108-112 (2006).

  • C. Buerger, N. Plock, P. Dehghanyar, C. Joukhadar, C. Kloft.
    Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis.
    Antimicrob. Agents Chemother., 50: 2455-2463 (2006).

  • L. Schönberg, T. Grobosch, D. Lampe, C. Kloft.
    New screening method for basic compounds in urine by on-line extraction–high-performance liquid chromatography with photodiode-array detection.
    J. Chromatogr. A, 1134: 177-185 (2006).

  • P. Dehghanyar, C. Bürger, M. Zeitlinger, F. Islinger, F. Kovar, M. Müller, C. Kloft,
    C. Joukhadar.
    Penetration of linezolid into soft tissues after single and multiple doses to healthy volunteers.
    Antimicrob. Agents Chemother., 49: 2367-2371 (2005).

  • N. Plock, C. Buerger, C. Kloft.
    Successful management of discovered pH dependence in vancomycin recovery studies: Novel HPLC method for plasma and in vitro microdialysis samples.
    Biomed. Chromatogr., 19: 237-244 (2005).

  • C. Kloft, E.-U. Graefe, P. Tanswell, A.M. Scott, R. Hofheinz, A. Amelsberg, M.O. Karlsson.
    Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients.
    Invest. New Drugs, 22: 39-52 (2004).

  • U. Warnke, C. Rappel, H. Meier, C. Kloft, M. Galanski, C.G. Hartinger, B.K. Keppler, U. Jaehde.
    Analysis of Platinum Adducts with DNA Nucleotides and Nucleosides by Capillary Electrophoresis Coupled to ESI-MS: Indications of Guanosine 5’-Monophosphate O6–N7 Chelation.
    ChemBioChem, 5: 1543-1549 (2004).

  • C. Buerger, C. Joukhadar, M. Mueller, S. Kljucar, C. Kloft.
    Development of a new HPLC method for the determination of linezolid and its application to in vitro and human microdialysis samples.
    J. Chromatogr. B, 796:155-164 (2003).

  • C. Kloft, W. Siegert, U. Jaehde.
    Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer.
    Br. J. Cancer, 89: 787-794 (2003).

  • H. Rommelspacher, M. Meier-Henco, M. Smolka, C. Kloft.
    The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets.
    Eur. J. Pharmacol., 441: 115-125 (2002).

  • S. Reif, M.C. Nicolson, D. Bissett, M. Reid, C. Kloft, U. Jaehde, H.L. McLeod.
    Effect of grapefruit juice intake on etoposide bioavailability.
    Eur. J. Clin. Pharmacol., 58: 491-494 (2002).

  • C. Kloft, W. Siegert, J. Beyer, U. Jaehde.
    Toxicity of high-dose carboplatin: ultrafiltered and not total plasma pharmacokinetics is of clinical relevance.
    J. Clin. Pharmacol., 42: 762-773 (2002).

  • S. Reif, D. Kingreen, C. Kloft, J. Grimm, W. Siegert, W. Schunack, U. Jaehde.
    Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients.
    Cancer Chemother. Pharmacol., 48: 134-140 (2001).

  • U. Warnke, J Gysler, B. Hofte, U.R. Tjaden, J. van der Greef, C. Kloft, W. Schunack, U. Jaehde.
    Separation and Identification of Platinum Adducts with DNA Nucleotides by Capillary Zone Electrophoresis and Capillary Zone Electrophoresis Coupled to Mass Spectrometry.
    Electrophoresis, 22: 97-103 (2001).

  • C. Kloft, C. Eickhoff, K. Schulze-Forster, H. R. Maurer, W. Schunack, U. Jaehde.
    Development and application of a simple assay to quantify cellular adducts of platinum complexes with DNA.
    Pharm. Res., 16: 470-473 (1999).

  • C. Kloft, H. Appelius, W. Siegert, W. Schunack, U. Jaehde.
    Determination of platinum complexes in clinical samples by a rapid flameless atomic absorption spectrometry assay.
    Ther. Drug Monit., 21: 631-637 (1999).

  • C. Kloft, H. Schöning, W. Siegert, U. Jaehde.
    AUC-guided dosing of carboplatin: an option for high-dose chemotherapy?
    Bone Marrow Transpl., 22 (Suppl. 3): 56-59 (1998).